Core Viewpoint - The company TianKang announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Methimazole tablets, a commonly used antithyroid medication [1] Group 1: Product Information - Methimazole is classified as a thiazole antithyroid drug that inhibits the activity of thyroid peroxidase (TPO), thereby blocking the coupling of iodide and tyrosine in the thyroid, which hinders the synthesis of T4 and triiodothyronine (T3) [1] - The primary use of Methimazole tablets is for the treatment of hyperthyroidism, particularly in patients with mild hyperthyroidism and those with mild to moderate goiter [1] - Additionally, Methimazole can be used as a preparatory medication for patients undergoing radioactive iodine treatment to prevent thyroid storm post-treatment [1] Group 2: Market Considerations - The future sales performance of Methimazole tablets may be influenced by industry policies and market conditions, indicating a level of uncertainty [1]